赛托生物 reported revenue of ¥0.61B for the period ended 2026-06-30, +20.7% year on year. Net income was ¥0.03B, a 5.1% net margin on a 25.4% gross margin. The largest revenue line is 甾体药物原料及其他中间体原料药 at 94% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.61B | +20.7% |
| Gross profit | ¥0.16B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | — |
| Gross margin | 25.4% | Net margin 5.1% |
| Revenue Q/Q | -13.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 甾体药物原料及其他中间体原料药 | ¥0.58B | 94.4% |
| 其他(补充) | ¥0.03B | 5.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.46B | 74.6% |
| R&D | ¥0.02B | 3.5% |
| SG&A | ¥0.07B | 11.2% |
| Tax & other | ¥0.01B | 1.6% |
| Item | Amount |
|---|---|
| Total assets | ¥2.95B |
| Total liabilities | ¥1.16B |
| Shareholders' equity | ¥1.80B |
| Equity / assets | 60.8% |
| Operating cash flow | ¥0.09B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 390% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
海辰药业 ・ 奥联电子 ・ 美联新材 ・ 天铁科技 ・ 熙菱信息 ・ 江龙船艇 ・ 移为通信 ・ 万里马 ・ 华凯易佰 ・ 新雷能 ・ ST朗进 ・ 欧普康视
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies